Thermo Fisher Scientific Inc. (NYSE:TMO) Position Lowered by Anchor Capital Advisors LLC

Anchor Capital Advisors LLC lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,167 shares of the medical research company’s stock after selling 1,762 shares during the quarter. Anchor Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $18,135,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Guyasuta Investment Advisors Inc. lifted its stake in Thermo Fisher Scientific by 0.8% during the fourth quarter. Guyasuta Investment Advisors Inc. now owns 105,483 shares of the medical research company’s stock worth $55,989,000 after purchasing an additional 820 shares during the last quarter. Choreo LLC lifted its holdings in Thermo Fisher Scientific by 109.8% in the fourth quarter. Choreo LLC now owns 3,354 shares of the medical research company’s stock worth $1,781,000 after acquiring an additional 1,755 shares during the last quarter. McAdam LLC bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $210,000. Mather Group LLC. lifted its holdings in shares of Thermo Fisher Scientific by 5.6% in the 4th quarter. Mather Group LLC. now owns 3,099 shares of the medical research company’s stock worth $1,645,000 after purchasing an additional 163 shares during the last quarter. Finally, Monumental Financial Group Inc. grew its stake in Thermo Fisher Scientific by 4.6% during the 4th quarter. Monumental Financial Group Inc. now owns 2,196 shares of the medical research company’s stock worth $1,166,000 after buying an additional 96 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.6 %

Shares of NYSE:TMO traded up $3.29 during midday trading on Monday, reaching $576.89. The company had a trading volume of 953,797 shares, compared to its average volume of 1,554,480. The company has a fifty day simple moving average of $573.60 and a two-hundred day simple moving average of $530.40. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The firm has a market cap of $220.20 billion, a price-to-earnings ratio of 36.82, a price-to-earnings-growth ratio of 2.41 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The business had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Research analysts predict that Thermo Fisher Scientific Inc. will post 21.56 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Analysts Set New Price Targets

Several equities analysts have recently commented on TMO shares. Robert W. Baird lowered their price target on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday. Barclays lifted their target price on Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a research note on Thursday. Raymond James raised their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Citigroup assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a “neutral” rating and a $620.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research report on Thursday. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $606.76.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 5,547 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $550.62, for a total transaction of $3,054,289.14. Following the completion of the sale, the chief executive officer now owns 43,608 shares of the company’s stock, valued at $24,011,436.96. The disclosure for this sale can be found here. Insiders have sold a total of 50,277 shares of company stock valued at $28,513,384 in the last 90 days. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.